TABLE 1.

Demographic characteristics of patients participating in delavirdine-ritonavir interaction study^a

Subject	Age (yr)	Race	HIV riskb	Wt (kg)	Smoking status	Duration of ritonavir treatment (mos)	Nucleosidesc	No. of concurrent medications
1	33	Black	Heterosexual	78	Never	5	3TC, ZDV	2
2	39	Black	Homosexual	75	Smoker	11	3TC, ZDV	6
3	44	White	Homosexual, IVDU	100	Smoker	12	3TC, d4T	6
4	40	White	Heterosexual	62	Smoker	2	3TC, d4T	3
5	38	White	Homosexual	67	Smoker	7	ddI, d4T	2
6	50	White	Homosexual	61	Smoker	10	3TC, ZDV	3
7	32	White	Homosexual, IVDU	67	Smoker	12	3TC, d4T	9
8	54	White	Homosexual	86	Never	4	3TC, ZDV	2
9	41	White	Blood transfusion recipient	108	Never	7	3TC, ZDV	6
10	47	Hispanic	Homosexual	90	Never	12	3TC, d4T	7
13	34	White	Homosexual	67	Smoker	1	None	7
14	39	White	Homosexual	90	Never	2	3TC, d4T	9
Mean or total	40.7	2 black, 9 white, 1 Hispanic	7 homosexual, 2 homosexual; IVDUs, 2 heterosexual, 1 blood transfusion recepient	79.0	7 smokers, 5 nonsmokers	7	10 3TC, 5 ZDV, 6 d4T, 1 ddI user	4.9
SD	6.51			14.4		4.3		2.5

^aAll 12 patients who completed the study were male.

^bIVDU, intravenous drug used.

^c3TC, lamivudine; ZDV, zidovudine; d4T, stavudine; ddI, dideoxyinosine.